Wedbush initiates coverage on BridgeBio with Outperform rating and $25 price target.

Wedbush initiates coverage on BridgeBio with Outperform rating and $25 price target.

Wedbush Securities has initiated coverage on BridgeBio Pharma (BBIO) with an "Outperform" rating and a price target of $25 per share, according to a recent analyst report [2]. This move underscores the growing optimism among Wall Street analysts regarding the biotech company's potential for growth and profitability.

BridgeBio Pharma has been a focal point for investors due to its strong pipeline of rare disease therapies and robust operational performance. The company's second-quarter 2025 results highlighted a significant revenue surge, driven primarily by its drug Attruby, which saw a substantial increase in prescriptions and net product revenue. This growth, coupled with the company's strong cash reserves and upcoming Phase 3 trial readouts, has positioned BridgeBio as a high-conviction biotech growth opportunity [1].

Wedbush's analyst rating and price target align with the broader market sentiment, which has been overwhelmingly positive. Nineteen analysts surveyed in the past 12 months have assigned a "Buy" or stronger rating to BBIO, with an average price target of $60.12, reflecting a 17.15% upside from the current stock price of $51.32 [1]. This consensus is driven by optimism about the company's ability to execute on its strategic priorities and deliver strong returns for investors.

The convergence of analyst optimism, operational execution, and financial strength creates a compelling investment case for BridgeBio. The company's strong balance sheet, with $756.9 million in cash reserves, supports its R&D programs and potential in-licensing opportunities without diluting shareholders [1]. Additionally, the company's pipeline of late-stage trials targeting rare diseases, such as FORTIFY, CALIBRATE, and PROPEL 3, positions it as a leader in this critical therapeutic area.

Despite the positive outlook, investors should remain cognizant of the risks associated with BridgeBio's reliance on a single drug for most of its current revenue. The company's persistent net losses and elevated operating expenses underscore the importance of upcoming clinical trial data and potential partnerships as key catalysts for future growth [2].

In conclusion, Wedbush's initiation of coverage on BridgeBio Pharma with an "Outperform" rating and a $25 price target reflects the growing consensus among analysts regarding the company's potential for transformative growth. As BridgeBio nears breakeven and gains momentum, investors seeking exposure to a high-conviction biotech opportunity should closely monitor the company's progress and upcoming trial readouts.

References:
[1] https://www.ainvest.com/news/bridgebio-pharma-bbio-poised-deliver-strong-returns-breakeven-gains-analyst-momentum-2508/
[2] https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bbio/bridgebio-pharma/news/why-bridgebio-pharma-bbio-is-up-96-after-surging-revenue-and